Revision as of 05:37, 22 September 2012 by Kazuko (Talk | contribs)

Project Overview

We try to develop new medicine for therapy of leukemia which is more free from side effects.
For this study, we are going to use Drosophila melanogaster, a model organism to establish transgenic fly carrying responsible genes for human leukemia.


Drosophila melanogaster has been used for a genetic study as model organism for a long time and brought us much discovery. And we are sure that the benefit continues from now on.
Therefore we KIT-Kyoto team aim at the production of the disease model Drosophila which expresses the responsible gene of MALT lymphoma that is one of leukemia that we were not able to achieve in a meeting of the last year. It is thought that we can contribute to elucidation of the mechanism of this disease and the development of the therapeutic drug by promoting this project.
In addition, we think about what we can do in order to continue researches using Drosophila melanogaster in the world. The structure and behavior of the gene cluster are often found by pushing forward the study about genes systematically and cooperatively.
So, this year we aim at the design of the parts with which a study that we use the Drosophila can expand in iGEM in future.
If these projects are realized, the study using D. melanogaster will step forward to the new one step again.


Establishment of transgenic flies carrying UAS-TNFAIP3.

We have injected 692 embryos (w-, delta2-3) with pUAS-TNFAIP3 DNA (1mg/ml in microinjection buffer). Out of them 144 were hatched to larvae and 83 were further eclosed to adults. These 83 adult flies were crossed with yw flies and their progeny flies were inspected to identify successfully transformed w+ red eye flies. The red eye screening is still ongoing. However, we have identified six transformant strains that are listed below. Chromosomal linkage of the transgene is now under investigation.